| Section | Provisional content |
|---|---|
| Retrieval / citation status | **Prominent note:** tool-based retrieval in this session returned **zero citable contexts**, so all claims below are **seed-anchored and require manual verification** against the cited seed PMIDs before curation use. |
| Executive judgment | **Partially supported (provisional).** The seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure via synaptonemal-complex dysfunction, but confidence is limited because no publication text was retrievable for direct verification in this run. |
| Evidence matrix summary | **PMID:25062452** — familial human genetics; homozygous nonsense variant in affected sisters with POI/primary amenorrhea; PubMed: https://pubmed.ncbi.nlm.nih.gov/25062452/ . **PMID:32402064** — model evidence for absent SYCE1 protein/reduced transcript and synapsis-related infertility mechanism; PubMed: https://pubmed.ncbi.nlm.nih.gov/32402064/ . **PMID:34718620** — in vitro/human cohort evidence that SYCE1 variants disrupt interaction with SYCP1 and/or C14ORF39/SIX6OS1 affecting SC assembly; PubMed: https://pubmed.ncbi.nlm.nih.gov/34718620/ . **PMID:35718780** — human NOA cases with SYCE1 CNVs and pachytene-stage arrest on H&E/IF; PubMed: https://pubmed.ncbi.nlm.nih.gov/35718780/ . |
| Clinical spectrum: 46,XX | Seed evidence supports **primary ovarian insufficiency / primary amenorrhea** in 46,XX individuals; detailed endocrine values, ovarian imaging, follicle depletion, and longitudinal data were not retrievable in this run. |
| Clinical spectrum: 46,XY | Seed evidence supports **non-obstructive azoospermia** with **pachytene-stage spermatogenic arrest** on histology/immunofluorescence in 46,XY individuals; semen details, hormones, and biopsy-marker specifics remain unverified here. |
| Variant / inheritance summary | Provisional inheritance model: **autosomal recessive / biallelic**. Seed evidence mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting SYCE1 interactions, and **SYCE1 CNVs**; exact zygosity/phasing, family counts, and ACMG classifications require manual confirmation. |
| Mechanistic causal chain | Provisional chain: **biallelic SYCE1 loss/damaging variant -> reduced or absent SYCE1 -> disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 -> synaptonemal-complex central element assembly failure -> homologous chromosome synapsis failure -> pachytene arrest/checkpoint activation -> germ-cell depletion -> 46,XX POI/primary amenorrhea or 46,XY NOA/spermatogenic arrest**. |
| Diagnostics / management implications | Provisional practice implications: include **SYCE1** on infertility/POI/NOA genetic panels with **CNV detection**; in 46,XY consider semen analysis, endocrine evaluation, and biopsy when indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management likely follows standard care pathways: hormone replacement for POI as indicated, fertility counseling, donor-oocyte discussion for POI, and cautious consideration of micro-TESE/ICSI in NOA. |
| Ontology suggestions | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. |
| Knowledge gaps | Major gaps are due to retrieval failure: no verified full texts, no figure/table access, no confirmed endocrine data (e.g., FSH/AMH), incomplete histology details, uncertain CNV phasing/zygosity, and limited direct human evidence for checkpoint activation or apoptosis. No 2023-2024 studies could be prioritized in this environment. |
| Curator leads | Provisional updates to consider after verification: (1) annotate the mechanism as a **meiotic synaptonemal-complex central element assembly defect**; (2) capture the dual-sex phenotype of **46,XX POI/primary amenorrhea** and **46,XY NOA/pachytene arrest**; (3) note support for **loss-of-function and CNV** mechanisms; (4) add the partner-interaction mechanism involving **SYCP1** and **C14ORF39/SIX6OS1**. |


*Table: This table provides a concise, seed-anchored provisional curation summary for SYCE1-related gametogenic failure. It is useful as a curator checklist because it organizes the mechanistic hypothesis, clinical spectrum, variant evidence, and verification needs in one place despite the lack of retrievable citable contexts.*